Oncomed Pharmaceuticals (OMED) Sees Unusually-High Trading Volume
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) saw strong trading volume on Friday . 3,356,692 shares changed hands during trading, an increase of 602% from the previous session’s volume of 478,194 shares.The stock last traded at $0.99 and had previously closed at $0.83.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Oncomed Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 2nd. ValuEngine upgraded Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Wells Fargo & Co reiterated a “market perform” rating and set a $1.50 price target (down from $8.00) on shares of Oncomed Pharmaceuticals in a report on Thursday, December 6th.
The firm has a market capitalization of $32.45 million, a price-to-earnings ratio of -6.19 and a beta of 1.81.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/oncomed-pharmaceuticals-omed-sees-unusually-high-trading-volume/2896886.html.
Oncomed Pharmaceuticals Company Profile (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.